February 1, 2011. Our Center strongly supports Senate Bill 1449, which will help to ensure that Virginia’s children are better protected from the adverse health effects of BPA.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Circulatory System Devices Panel Meeting: Slide Presentation
January 25, 2011. Researchers have reported that more than 20 percent of the almost one million AEDs in circulation were recalled by the FDA. Hundreds of people have died due to AED malfunctions. Innovation in design isn’t worth anything if the product doesn’t work when needed.
Read More »Letter from the Patient, Consumer, and Public Health Coalition to FDA about Improving Medical Device Safety
January 18, 2011. We strongly believe that improving the standards needed to prove safety and effectiveness of medical devices will ensure that U.S. companies flourish and create jobs at the same time as they contribute to public health.
Read More »NCHR Testimony at the FDA on NB (Contrave)
December 7, 2010. FDA Advisory Committee members often ask for post-market studies. In this case, that could be dangerous.
Read More »NCHR Testimony on Gardasil
December 7, 2010. The FDA approved Gardasil on the basis of short-term research, and we don’t yet know how long Gardasil provides protection or when a booster shot will be needed.
Read More »